Johnson & Johnson (JNJ)

Johnson & Johnson's stock has increased approximately 43% over the past year. The FDA approved Icotyde for plaque psoriasis, and the European Commission approved AKEEGA for prostate cancer. The Ottava surgical robot met safety and performance endpoints in a gastric bypass study. Management is considering selling its DePuy Synthes orthopedics unit. CVS recently dropped Stelara from its main formulary. The stock price as of May 5, 2026, was $225.55 per share, an increase of 46.02% from $154.47 per share on May 6, 2025. J&J shares decreased to $223.74 USD, the lowest since January 2026, as of May 4, 2026.

The healthcare sector, including Johnson & Johnson, generally experiences seasonal strength from April 25 to December 4. Historically, a "Buy Date" of May 29 and a "Sell Date" of August 19 has resulted in a geometric average return of 2.35% above the S&P 500 Total Return Index benchmark. Over the past 56 years, Johnson & Johnson stock has historically risen by an average of 12.4% over a 52-week period.

Johnson & Johnson is a multinational corporation specializing in pharmaceuticals and medical technologies, operating through Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on treatments across immunology, oncology, neuroscience, infectious diseases, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment offers medical technologies used in surgery, orthopedics, vision care, and interventional solutions. The Consumer Health division was spun off as Kenvue in 2023, allowing Johnson & Johnson to focus on prescription medication and medical equipment.

Johnson & Johnson operates in over 60 countries and sells products in more than 175 countries, employing approximately 138,000 people worldwide. It has manufacturing facilities across various regions, including ten in Pennsylvania. Johnson & Johnson Innovation has hubs in Boston, London, South San Francisco, and Shanghai. Switzerland is also an important location with campuses in Basel, Bern, Neuchâtel, and Zug.

Johnson & Johnson has consistently maintained a strong brand reputation, being named to Fortune's "World's Most Admired Companies" list for the 24th consecutive year in January 2026 and to Fortune's "America's Most Innovative Companies" list for the fourth consecutive year in April 2026. Despite its positive reputation, Johnson & Johnson has faced legal and ethical challenges related to hip implant failures, Risperdal marketing claims, transvaginal mesh lawsuits, and talc-related cancer cases.

Johnson & Johnson's ownership is predominantly held by institutional investors, who controlled approximately 73.57% of the company's shares as of December 2024 and 73.12% in March 2025. Major institutional shareholders include The Vanguard Group, Inc., BlackRock, Inc., and State Street Corp. Other significant holders include Geode Capital Management, LLC, JPMorgan Chase & Co., and Morgan Stanley. Insider ownership is generally well under 1%.